Payment overview · 2025
General Payments
$445.62
24 reported records · 9 companies
Healthcare provider profile · identity verified
Brian E Lieb, DO
Allopathic & Osteopathic Physicians|Family Medicine · CARROLLTOWN, PA · NPI 1871598268
Verified facts
What the public records show
CMS Open Payments records show Brian E Lieb, DO received $445.62 in general payments during 2025 across 24 reported records.
Exact Sciences Corporation accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 316 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $100.39 | 22.5% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $68.73 | 15.4% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $64.23 | 14.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $58.81 | 13.2% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $55.62 | 12.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.05 | 7.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.25 | 5.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.47 | 5.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.07 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $445.62 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $100.39 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $68.73 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $64.23 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $55.62 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.50 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $28.31 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 316 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 123 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 201 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
123 | 32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
201 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
316 | 53 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1281 | 342 |
| Lisinopril | Lisinopril | 1117 | 288 |
| Amlodipine Besylate | Amlodipine Besylate | 787 | 222 |
| Hydrochlorothiazide | Hydrochlorothiazide | 588 | 168 |
| Metformin Hcl | Metformin Hcl | 456 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 445 | 105 |
| Metoprolol Tartrate | Metoprolol Tartrate | 431 | 124 |
| Losartan Potassium | Losartan Potassium | 418 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 371 | 107 |
| Omeprazole | Omeprazole | 325 | 95 |
| Eliquis | Apixaban | 316 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 315 | 89 |
| Furosemide | Furosemide | 305 | 82 |
| Sertraline Hcl | Sertraline Hcl | 293 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 235 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 223 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 53 |
| Prednisone | Prednisone | 205 | 133 |
| Jardiance | Empagliflozin | 201 | 47 |
| Potassium Chloride | Potassium Chloride | 191 | 53 |
| Allopurinol | Allopurinol | 178 | 50 |
| Meloxicam | Meloxicam | 170 | 38 |
| Atenolol | Atenolol | 164 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 159 | 36 |
| Carvedilol | Carvedilol | 146 | 40 |
| Gabapentin | Gabapentin | 143 | 37 |
| Glipizide Er | Glipizide | 129 | 38 |
| Farxiga | Dapagliflozin Propanediol | 123 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 108 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 33 |
| Trulicity | Dulaglutide | 103 | 21 |
| Xarelto | Rivaroxaban | 97 | 23 |
| Alendronate Sodium | Alendronate Sodium | 95 | 26 |
| Trazodone Hcl | Trazodone Hcl | 95 | 21 |
| Ezetimibe | Ezetimibe | 94 | 28 |
| Finasteride | Finasteride | 94 | 28 |
| Simvastatin | Simvastatin | 85 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 21 |
| Famotidine | Famotidine | 78 | 21 |
| Ozempic | Semaglutide | 78 | 16 |
| Warfarin Sodium | Warfarin Sodium | 75 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 73 | 15 |
| Donepezil Hcl | Donepezil Hcl | 71 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 16 |
| Metformin Hcl Er | Metformin Hcl | 67 | 15 |
| Januvia | Sitagliptin Phosphate | 64 | 16 |
| Celecoxib | Celecoxib | 61 | 18 |
| Montelukast Sodium | Montelukast Sodium | 60 | 18 |
| Synthroid | Levothyroxine Sodium | 60 | 15 |
| Glipizide | Glipizide | 58 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 56 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 15 |
| Amoxicillin | Amoxicillin | 51 | 44 |
| Tradjenta | Linagliptin | 50 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 31 |
| Gemfibrozil | Gemfibrozil | 42 | 12 |
| Propranolol Hcl | Propranolol Hcl | 41 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 26 |
| Valacyclovir | Valacyclovir Hcl | 41 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | 12 |
| Lorazepam | Lorazepam | 36 | suppressed |
| Azithromycin | Azithromycin | 34 | 31 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 30 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 19 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | suppressed |
| Invokana | Canagliflozin | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 20 |
| Irbesartan | Irbesartan | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Prolia | Denosumab | 19 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Admelog Solostar | Insulin Lispro | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Nadolol | Nadolol | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 13 |
| Nystatin | Nystatin | 15 | 12 |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $445.62 · 24 records | Exact Sciences Corporation | AIRSUPRA, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, NURTEC ODT, REXULTI, WATCHMAN FLX, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error